Publications by authors named "L Grossi"
Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Only limited real-life data on the long-term outcomes of CD patients treated with UST are available. This study assessed UST's long-term effectiveness and safety in a large population-based cohort of moderate to severe CD patients.
View Article and Find Full Text PDFUnlabelled: Neutralizing antibody titers and binding antibody levels are considered correlates of protection against severe SARS-CoV-2 infection. The clinical utility of serology should be reevaluated in light of the emergence of escape variants, as commercial antibody-binding assays have not been adapted to the virus' antigenic evolution. We compared anti-SARS-CoV-2 antibody titers in four quantitative serological tests based on variable ancestral spike antigens (three in-house ELISAs and the prototype VIDAS SARS-CoV-2 IgG QUANT assay) and neutralization assays against the pseudotyped Wuhan, BA.
View Article and Find Full Text PDFDrug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study.
Glob Reg Health Technol Assess
October 2024
Article Synopsis
- The study evaluates the use of biologic and targeted synthetic drugs for treating psoriatic arthritis (PsA) in Italy, specifically focusing on the role of biosimilar drugs.
- Conducted over four years at eight hospital pharmacies, the research tracked patients new to treatment, assessing their persistence and adherence to medication using the proportion of days covered (PDC).
- Findings revealed that patients on biosimilars showed better adherence and persistence than those on originators, and utilizing biosimilars resulted in significant cost savings, highlighting their potential benefits in healthcare resource optimization.
Pseudomonas aeruginosa is a frequent cause of antimicrobial-resistant hospital-acquired pneumonia, especially in critically ill patients. Inflammation triggered by P. aeruginosa infection is necessary for bacterial clearance but must be spatially and temporally regulated to prevent further tissue damage and bacterial dissemination.
View Article and Find Full Text PDFArticle Synopsis
- This study looks at how often and consistently patients with psoriasis use different drugs over 1 to 5 years, specifically focusing on medications like Adalimumab and others.
- Researchers used real-life data to measure how well patients adhered to their treatment plans using the Proportion of Days Covered (PDC) method.
- While adherence to treatment was generally good, the study found that persistence (the duration patients stay on treatment) dropped significantly after the second year, highlighting the need for better strategies to encourage long-term treatment.